The ALWP which relies on a large registry based in Paris, is specifically devoted to the promotion and analyses of all primary and secondary myeloid and lymphatic acute leukemia aspects associated with the transplantation of stem cells from Autologous and all donor types including T deplete and T replete Haploidentical transplants as well as cord blood transplantation, including prospective and retrospective studies, and education in this field.
Over the last decades, studies conducted by the ALWP members yielded a significant amount of scientific knowledge creating the basis for continuously improving patient care.
With the support of the different ALWP subcommittees leaders (F. Ciceri, J. Esteve, S. Giebel, NC. Gorin, F. Baron, B. Savani and C. Schmid), the data managers (E. Polge, A. Mailhol, M. Houhou, E. Penisson (part time)) with the help of invited Post Doc fellows, (Eder S. (Austria), Lorentino F. (Italy) and Sun Y. (China)) our dedicated statistician M. Labopin, ALWP members and all EBMT participating centres, the studies portfolio of the ALWP has grown quickly, and generated an amazing number of published manuscripts and communications at major meetings such as the EBMT, ASH, EHA and ASBMT/CIBMTR Tandem meetings.
The huge scientific productivity of the ALWP over the last months is a good illustration of the success of such strategy. Thus, with the support of all of you, we deeply believe in the capacity of the ALWP in cooperation with the other working parties and EBMT leadership, to continue daunting these challenges.
We do thank you all for your continuous support to the ALWP endeavours and you can count on our commitment to boost the scientific drive of the investigators towards conducting large, welldesigned.
Winter meeting followed by the 10th Symposium «Advances in Acute Leukemia: what's new in 2017?»
Paris (France) - November 3-4, 2017
2015 11 Minutes of the ALWP business meeting Paris 2015
2015_03 Minutes of the ALWP business meeting Istanbul 2015
2014 11 Minutes of the ALWP business meeting Paris 2015
2014_03_Minutes of the ALWP bussiness meeting in Milan 2014.pdf
2013_04_Minutes of the ALWP business meeting London 2013.pdf
2013 11 Minutes of the ALWP business meeting in Marseille 2013.pdf
2012_04_Minutes of the ALWP business meeting Geneva 2012.pdf
2012_11_Minutes of the ALWP business meeting Milan 2012.pdf
M. LABOPIN - Statistician
B. SAVANI - Reduced Intensity Conditioning Subcommittee
F. CICERI - Alternative Donors Subcommittee
S. GIEBEL - Acute Lymphoid Leukemia Subcommittee
J. ESTEVE - Molecular Markers Subcommittee
C. SCHMID - Immunotherapy Subcommittee
NC. GORIN - Autologous transplantation Subcommittee
F. BARON - Cord Blood Subcommittee
E. POLGE - Study Coordinator head
A. MAILHOL - Study Coordinator
M. HOUHOU - Study Coordinator
E. PENISSON - Study Coordinator (part time)
M. KIMOUCHE - Study Coordinator (part time)
A. DJABALI - Study Coordinator (part time)
S. EDER J. - Invited Resident
F. LORENTINO - Invited Resident
SUN. Y - Invited Resident
Click HERE to view the publication list
EBMT-ALWP Newsletter February 2016.pdf
2015 04 EBMT-ALWP Newsletter March 2015
Studies coordinated by the ALWP
Click HERE to view the Current Research list
ivFB2 vs ivFB4 for allogeneic transplant in AML
Impact of Campath versus ATG after unrelated allogeneic stem cell transplantation with RIC as treatment for AML in CR1
Comparison of TBI/Cy vs Bu/Cy preparative regimens before allogeneic SCT in 1st relapse for AML
Survey on HSCT for Acute Promyelocytic Leukemia (APL/M3) in the ATO era
Outcome of Allogeneic Hematopoietc Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1)
Outcome of RIC MUD alloHSCT in ALL patients on behalf of the Acute Leukaemia Working Party (EBMT)
Haematopoietic Stem Cell Transplantation for Plasmacytoid Dendritic Cell Leukaemia/Lymphoma (pDCL)
A randomised Phase III study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic stem cell transplanttion from related and unrelated donors as consolidation therapy for older patients with AML in 1st complete remission
How to get involved?
Please contact the Chairperson or the Secretary.